CD19 and lymphoid neoplasm: Additionally, clinical trials have demonstrated successful application of anti-CD19 CAR-modified umbilical cord blood-derived and haploidentical NK cells in patients with CD19 lymphoid tumors and acute myeloid leukemia, respectively (76, 77).